Hvivo (HVO)

Sector:

Health Care

Index:

FTSE AIM All-Share

28.50p
   
  • Change Today:
      0.60p
  • 52 Week High: 30.60p
  • 52 Week Low: 18.00p
  • Currency: UK Pounds
  • Shares Issued: 680.37m
  • Volume: 1,724,303
  • Market Cap: £193.91m

Venn Life Sciences finds 'model client' in Carrick Therapeutics

By Josh White

Date: Friday 18 Jan 2019

LONDON (ShareCast) - (Sharecast News) - Integrated drug development company Venn Life Sciences announced a partnership with Carrick Therapeutics on Friday.
The AIM-traded firm said Carrick Therapeutics was building a portfolio of first-in-class treatments that targeted multiple mechanisms of the most aggressive forms of cancer, and were optimised to a patient's individual tumour through identification of predictive biomarkers.

It said Carrick had built a network of partners and collaborators to progress its technology portfolio, with Venn "delighted" to join that network as a provider of early development and clinical research capabilities.

"In so many respects, Carrick Therapeutics represents the model client for Venn," said Venn Life Sciences chief executive officer Tony Richardson.

"Highly innovative with a portfolio approach focusing on their core intellectual property, while working on an outsource basis with a well-developed network of support partners.

"At Venn we have built a suite of capabilities designed to address all of the development requirements of this model and are delighted to partner with Carrick in the development of their first in class treatments."

Elaine Sullivan, chief executive officer of Carrick Therapeutics, added that by linking a network of clinicians and scientists in internationally-leading research institutes and hospitals, her firm would use its multi-asset portfolio to drive the development of "groundbreaking" cancer therapies from laboratory to clinic.

"Together with our academic and biotech partners, we are looking to detect predictive biomarkers in each of our projects to enable us to identify those who would benefit most from our therapies.

"These targeted treatments will bring a higher quality of life to cancer patients around the world," Sullivan said.

"We are partnering with Venn to provide development and clinical capabilities and they are a welcome addition to our network."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Hvivo Market Data

Currency UK Pounds
Share Price 28.50p
Change Today 0.60p
% Change 2.15 %
52 Week High 30.60p
52 Week Low 18.00p
Volume 1,724,303
Shares Issued 680.37m
Market Cap £193.91m

Hvivo Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
95.74% below the market average95.74% below the market average95.74% below the market average95.74% below the market average95.74% below the market average
65.71% below the sector average65.71% below the sector average65.71% below the sector average65.71% below the sector average65.71% below the sector average
Price Trend
78.19% above the market average78.19% above the market average78.19% above the market average78.19% above the market average78.19% above the market average
94.59% above the sector average94.59% above the sector average94.59% above the sector average94.59% above the sector average94.59% above the sector average
Income
94.38% below the market average94.38% below the market average94.38% below the market average94.38% below the market average94.38% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
52.34% above the market average52.34% above the market average52.34% above the market average52.34% above the market average52.34% above the market average
72.22% above the sector average72.22% above the sector average72.22% above the sector average72.22% above the sector average72.22% above the sector average

What The Brokers Say

Strong Buy 3
Buy 3
Neutral 0
Sell 0
Strong Sell 0
Total 6
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Hvivo Dividends

  Latest Previous
  Final Special
Ex-Div 18-Apr-24 04-May-23
Paid 20-May-24 09-Jun-23
Amount 0.20p 0.45p

Trades for 31-Oct-2024

Time Volume / Share Price
16:37 275 @ 28.50p
16:20 71,610 @ 28.25p
16:16 7,150 @ 28.40p
15:56 3,469 @ 28.65p
14:48 150,000 @ 28.15p

Hvivo Key Personnel

CEO Yamin Mo' Khan

Top of Page